Abstract:Background Recent studies indicate exosomes play an important role in cell-to-cell communication, cancer metastasis, neovascularization, the regulation of the tumor immune microenvironment, and drug resistance in various tumors. However, the prognostic and therapeutic value of exosome-related genes in bladder cancer (BCa) remains to be determined. Hence, the goal of this study was to identify and validate a novel prognostic model based on exosome-associated genes for BCa patients Methods Differentially expressed exosome-related genes (DEGs) were analyzed using the Cancer Genome Atlas (TCGA) databases. DEGs closely associated with BCa patient survival prognosis were identified using Cox regression; and these genes are used for molecular typing. Moreover, we constructed a 17 multigene model using the least absolute shrinkage and selection operator (LASSO) Cox regression model. The five external cohorts (i.e., GSE13507, GSE32894, GSE31684, GSE48075, and IMvigor210) of BCa patients were used to validate the accuracy by KM plot, ROC and calibration curves. Subsequently, we assessed immune infiltration using seven published algorithms: TIMER, CIBERSORT, CIBERSORT-ABS, QUANTISEQ, MCPCOUNTER, XCELL, and EPIC. Furthermore, the correlation results between risk groups (scores) and overall survival, recognised immunoregolatory cells or common chemotherapeutic agents, clinicopathological data and immune checkpoint-related genes of BCa patients, were analyzed based on wilcox rank test, chi-square test, cox regression and spearman's correlation method. Additionally, we also preformed that the expression level of partial modeled genes was significantly associated with objective responses to anti-PD-1/PD-L1 treatment in the IMvigor210, GSE111636, GSE176307 or our Truce01 cohort. Results In BC patients, 156 exosome-related prognostic DEGs were identified, and were clustered into three classes. Subtypes C3 predicts worse OS, DSS, and PFS in patients with BCa. The prognostic model of 17 exosome-related genes showed good prediction performance by the TCGA training set, internal test set and five external verification sets. Our study also additionally confirmed that model riskscore was closely related with drug susceptibility, immune cell infiltration, and the prediction of immunotherapy efficacy. The high-risk group was characterized by a higher number of infiltrating macrophages M2 cells, and cancer-associated fibroblasts (CAFs). Lastly, we verified the protein and mRNA expression of six interested model-related genes (including AKR1B1, CGB5, CSPG4, P4HB, POLR3G and RAC3) from the Human Protein Atlas (HPA) and 10 paired BCa tissues collected by us. Conclusions In summary, the exosome-associated gene signature established by us exhibited a high predictive performance for the prognosis, immunotherapeutic responsiveness, and chemotherapeutic sensitivity of BCa. And, The model also might function as a chemotherapy and immune checkpoint inhibitor (ICI) treatment guidance.

Specific subsets of urothelial bladder carcinoma infiltrating T cells associated with poor prognosis

Urine scRNAseq reveals new insights into the bladder tumor immune microenvironment

Single-cell Sequencing Data Reveals Aggressive CD68-type Macrophages and Prognostic Models in Bladder Cancer.

Clinical and RNA Expression Integrated Signature for Urothelial Bladder Cancer Prognosis.

Immune Profiling Reveals Molecular Classification and Characteristic in Urothelial Bladder Cancer

Single-cell atlases link macrophages and CD8 + T-cell subpopulations to disease progression and immunotherapy response in urothelial carcinoma

A novel 6-gene signature derived from tumor-infiltrating T cells and neutrophils predicts survival of bladder urothelial carcinoma

Identification of endothelial-related molecular subtypes for bladder cancer patients

Investigating cellular similarities and differences between upper tract urothelial carcinoma and bladder urothelial carcinoma using single-cell sequencing

Single-nucleus RNA-sequencing analysis reveals transcriptome differences in TIGIT+ exhausted T-cell associated with poor prognosis in muscle-invasive bladder cancer (MIBC).

Screening and Identifying Immune-Related Cells and Genes in the Tumor Microenvironment of Bladder Urothelial Carcinoma: Based on TCGA Database and Bioinformatics

Distinct Infiltration of T Cell Populations in Bladder Cancer Molecular Subtypes

Comprehensive genomic profiling of upper tract urothelial carcinoma and urothelial carcinoma of the bladder identifies distinct molecular characterizations with potential implications for targeted therapy & immunotherapy

Single-cell RNA sequencing highlights the role of inflammatory cancer-associated fibroblasts in bladder urothelial carcinoma

Comprehensive Analyses of a Tumor-infiltrating Lymphocytes-Related Gene Signature regarding the Prognosis and Immunologic Features for Immunotherapy in Bladder Cancer on the basis of WGCNA

Multi-omics analysis of tumor mutation burden combined with immune infiltrates in bladder urothelial carcinoma

Immune landscape of distinct subtypes in urothelial carcinoma based on immune gene profile

Development and Validation of a Exosome-Related Gene Signature for Predicting Prognosis, Immune Infiltration and Immunotherapeutic Response in Bladder Cancer

Immune‐related signature predicts the prognosis and immunotherapy benefit in bladder cancer

Profiles of tumor-infiltrating immune cells and prognostic genes associated with the microenvironment of bladder cancer

Identification and Validation of an Excellent Prognosis Subtype of Muscle-Invasive Bladder Cancer Patients with Intratumoral CXCR5+ CD8+ T Cell Abundance.